Waters (NYSE:WAT – Get Free Report) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
Several other research analysts have also issued reports on the company. Royal Bank Of Canada increased their target price on Waters from $475.00 to $525.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 4th. Jefferies Financial Group lifted their price target on Waters from $450.00 to $455.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Morgan Stanley set a $430.00 price target on Waters in a research report on Wednesday, August 5th. Deutsche Bank upped their price target on Waters from $400.00 to $440.00 in a research note on Thursday, October 15th. Finally, Leerink Partners increased their price objective on Waters from $420.00 to $450.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $475.48.
View Our Latest Stock Analysis on Waters
Waters Trading Down 0.0%
Shares of WAT opened at $460.19 on Friday. The firm’s 50-day moving average price is $440.45 and its 200-day moving average price is $374.12. The firm has a market capitalization of $45.23 billion, a price-to-earnings ratio of 197.51, a PEG ratio of 2.62 and a beta of 1.16. The company has a current ratio of 1.89, a quick ratio of 1.28 and a debt-to-equity ratio of 0.29. Waters has a 1-year low of $282.77 and a 1-year high of $483.33.
Waters (NYSE:WAT – Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.00 by $0.10. Waters had a net margin of 1.75% and a return on equity of 9.91%. The company had revenue of $1.77 billion for the quarter, compared to analysts’ expectations of $1.75 billion. During the same quarter in the previous year, the company earned $3.40 earnings per share. Waters’s quarterly revenue was up 120.9% on a year-over-year basis. Sell-side analysts anticipate that Waters will post 14.65 EPS for the current year.
Hedge Funds Weigh In On Waters
Institutional investors and hedge funds have recently made changes to their positions in the business. EP Wealth Advisors LLC lifted its holdings in shares of Waters by 12.5% during the third quarter. EP Wealth Advisors LLC now owns 1,647 shares of the medical instruments supplier’s stock valued at $724,000 after purchasing an additional 183 shares during the last quarter. Pathstone Holdings LLC boosted its position in shares of Waters by 7.4% in the 3rd quarter. Pathstone Holdings LLC now owns 9,952 shares of the medical instruments supplier’s stock worth $4,264,000 after purchasing an additional 690 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Waters by 6.8% in the 3rd quarter. Marshall Wace LLP now owns 620,609 shares of the medical instruments supplier’s stock worth $272,689,000 after buying an additional 39,277 shares during the last quarter. Empowered Funds LLC grew its stake in shares of Waters by 19.3% in the 3rd quarter. Empowered Funds LLC now owns 7,160 shares of the medical instruments supplier’s stock worth $3,146,000 after buying an additional 1,156 shares during the last quarter. Finally, Tocqueville Asset Management L.P. purchased a new stake in shares of Waters in the 3rd quarter worth approximately $228,000. Institutional investors own 94.01% of the company’s stock.
About Waters
Waters Corporation develops and supplies analytical instruments, software, and consumables used to identify, measure, and characterize chemical and biological materials. Its products include liquid chromatography and mass spectrometry systems, which help customers analyze complex samples. The company serves pharmaceutical and biotechnology businesses, academic and government laboratories, and customers in fields such as food, environmental testing, and materials science. Waters operates internationally, with customers and operations across multiple regions.
Further Reading
- Five stocks we like better than Waters
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.
